Envista Holdings Corporation (NVST)
Fair ValueFundamental
56
मूल्य
$23.13
मार्केट कैप
$3.87B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Envista makes the products dentists and orthodontists use every day: dental implants, clear aligners and orthodontic brackets, plus the equipment and consumables — imaging systems, drills, cements, infection-control supplies — that keep a dental office running. It sells through its own sales force and a network of dealers to over 130 countries, serving both specialists who place implants and general practitioners who handle routine care. More than half its sales come from outside the United States.
यह पैसा कैसे कमाती है
Envista books revenue when it ships implants, aligners, equipment or consumables to dealers and dental practices; consumables and implants are recurring, replenished purchases, while imaging systems and other capital equipment are one-off, lumpier sales tied to a practice's investment cycle. Its two segments split roughly two-thirds specialty products (implants, orthodontics) to one-third equipment and consumables, and its largest single distributor, Henry Schein, alone channels about 12% of total sales to end customers.
सेगमेंट के अनुसार राजस्व
Dental implant systems, regenerative products and orthodontic brackets, aligners and lab products for specialists and general dentists.
Dental imaging systems, endodontic equipment, restorative materials, cements and infection-prevention supplies used in daily practice.
प्रतिस्पर्धी बढ़त (Moat)
स्केल · संकीर्णEnvista describes itself as running one of the largest customer-facing sales teams in the dental industry, backed by a global dealer network reaching over 130 countries. That distribution scale is hard for smaller rivals to match, but the underlying implant and equipment categories are competitive and price-sensitive, so the advantage is narrow rather than a lock on the market.
मांग को क्या चलाता है
मध्यम रूप से चक्रीयRoutine dental consumables track fairly steady patient visit volumes, but elective procedures like implants and big-ticket equipment purchases are more discretionary and get postponed when practices or patients tighten spending. The mix of the two makes overall demand more resilient than typical consumer discretionary goods, but not fully immune to economic cycles.
प्रमुख जोखिम
- Distributor dependence — A substantial portion of sales flows through a limited number of distributors, chiefly Henry Schein, with no assurance any of them will keep purchasing at current levels or that lost volume could be quickly replaced.
- Distributor inventory swings — The company relies on predictions of distributor and customer inventory levels to plan production; when those inventories build or run down differently than expected, reported results can diverge sharply from underlying demand.
- Acquisition and divestiture risk — Envista routinely acquires and divests businesses to fit its portfolio strategy, and warns that earn-outs, indemnification obligations, goodwill impairments and unsatisfied deal conditions could all produce unpredictable financial results.
ग्राहक Concentration
शीर्ष ग्राहकों का राजस्व में 12% हिस्सा है
Henry Schein, the company's largest distributor, accounted for approximately 12% of sales in 2025 and is expected to remain the top contributor for the foreseeable future, without a master distribution agreement guaranteeing that relationship.
खरीदने के पक्ष में तर्क
Buyers argue that Envista's scale in global dental distribution and its position across both the specialist implant market and everyday consumables give it a resilient, recurring revenue base that should benefit as dental procedure volumes recover outside the U.S.
बेचने के पक्ष में तर्क
Sellers fear that heavy reliance on a handful of distributors, led by Henry Schein, leaves Envista exposed to a single relationship it does not fully control, and that elective procedure volumes remain vulnerable if patients keep deferring discretionary dental work.
Written by the editors, published on 18 अगस्त 2026
Direct competitors
Who this company fights with for the same customers
Generated on 19 सितंबर 2026 with claude-haiku-4-5 — shared with all users
Dentsply Sirona competes across almost the whole Envista catalogue at once — implants (Astra Tech, MIS), orthodontics, imaging equipment and chairside consumables sold to the same dental practices and distributors.
Align's Invisalign system is the benchmark Envista's Spark aligners are trying to take share from, and both also sell intraoral scanners to the orthodontists who prescribe them.
The former 3M oral-care business competes with Envista's Kerr and Ormco brands in restorative materials and in orthodontic brackets and appliances sold to general dentists and orthodontists.
Straumann is the global leader in premium dental implants and the direct rival of Envista's Nobel Biocare, and it also sells clear aligners and digital-dentistry workflows to the same implantologists and orthodontists.
Osstem is one of the world's largest implant makers by volume and attacks the value tier where Envista's Implant Direct brand competes, especially in Asia and emerging markets.
बैलेंस शीट और तरलता
राजस्व
$2.86B
पिछले 12 महीने (3/7/2026 तक)
शुद्ध आय
$95M
पिछले 12 महीने (3/7/2026 तक)
Free Cash Flow
$230M
कुल इक्विटी
$3.11B
कुल देनदारियाँ
$2.57B
Current Ratio
2.43
Interest Coverage
-
Debt/EBITDA
4.78
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$23.51
वर्तमान मूल्य
$23.13
Margin of Safety
+1.6%
Fair Value सीमा
$15.28 - $31.74
इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
40.47
ROE
1.5%
P/B Ratio
1.23
P/FCF
15.19
Gross Margin
55.2%
ROIC
4.5%
लाभप्रदता Radar
मूल्य सृजन (प्रतिस्पर्धी बढ़त)
ROIC
4.5%
WACC
6.9%
ROIC − WACC
-2.4 pp
ROIC पूंजी की लागत से कम है — कंपनी निवेशित हर डॉलर पर मूल्य नष्ट कर रही है।
Fundamental विश्लेषण मानदंड
पास (17)
- Gross Margin 55.2%
- P/FCF 15.19
- P/B Ratio 1.23
- Debt/Equity ratio
- Operating Margin 9.6%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 7.1%
- Analyst Consensus 55% Buy
- Earnings Surprise avg 15.7%
- Earnings Quality (OCF/NI) 3.19
- Share Dilution -2.5%
- Net Margin Trend 3.3% vs 2.1%
- Piotroski F-Score 7/9
फेल (9)
- EPS shows upward trend
- EPS CAGR -23.35%
- Price CAGR -3.07%
- ROIC 4.5%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Fairly valued)
- ROE 3.1%
- PEG Ratio 6.27
अनुपलब्ध (2)
- Dividend Payout NaN%
- Interest Coverage
Piotroski F-Score
मजबूत वित्तीय स्वास्थ्य
Earnings गुणवत्ता
उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
संस्थागत होल्डिंग
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Paul A. Keel | President, CEO & Chairman | 55 |
| Mr. Eric D. Hammes | Senior VP & CFO | 50 |
| Mr. Mark E. Nance J.D. | Senior VP, General Counsel & Secretary | 56 |
| Mr. Robert Befidi Jr. | Senior VP & President of Diagnostics | 50 |
| Ms. Veronica Acurio | Senior VP & President of Orthodontics | 54 |
| Mr. Coree Thomas | VP & Chief Accounting Officer | 47 |
| Mr. Andrew Chen | Chief Information Officer | - |
| Mr. Jim Gustafson | Vice President of Investor Relations | - |
| Paul Sumilas | Chief Compliance Officer | - |
| Mr. Mischa M. Reis | Senior Vice President of Strategy & Corporate Development | 52 |
Audit जोखिम
2
बोर्ड जोखिम
4
मुआवजा जोखिम
4
शेयरधारक अधिकार जोखिम
5
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
दस्तावेज़
- दस्तावेज़ देखें
वार्षिक रिपोर्ट (10-K)
कंपनी के कारोबार, वित्तीय नतीजों और जोखिमों का वार्षिक सिंहावलोकन।
दाखिल तिथि: 2026-02-12
- दस्तावेज़ देखें
तिमाही रिपोर्ट (10-Q)
पिछले तीन महीनों के वित्तीय प्रदर्शन का अपडेट।
दाखिल तिथि: 2026-08-05
- दस्तावेज़ देखें
विशेष रिपोर्ट (8-K)
किसी बड़ी घटना, जैसे नेतृत्व में बदलाव या बड़ी घोषणा, की सूचना।
दाखिल तिथि: 2026-09-17
via SEC EDGAR
आय का इतिहास
via SEC EDGAR
Latest News
Recent headlines for NVST, sourced from Markets Gazette.